<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348828</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0003</org_study_id>
    <nct_id>NCT01348828</nct_id>
  </id_info>
  <brief_title>Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System</brief_title>
  <official_title>Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endologix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endologix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and feasibility of the Endologix Fenestrated
      Stent Graft System for the endovascular repair of juxtarenal or pararenal aortic aneurysms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Endologix Fenestrated Stent Graft System that will be used in this study has three
      components, listed below:

        1. Endologix unibody bifurcated stent graft

        2. Endologix fenestrated proximal extension stent graft

        3. Endologix renal stent graft
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Major adverse events defined as:
All-cause death
Bowel ischemia
Myocardial infarction
Paraplegia
Renal failure
Respiratory failure
Stroke
Blood loss &gt;=1,000cc</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility/effectiveness</measure>
    <time_frame>30 Days</time_frame>
    <description>Successful device delivery and deployment with patency of the renal and aortic endografts without Type I/III endoleak.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural/in-hospital evaluations</measure>
    <time_frame>Procedurally and to hospital discharge</time_frame>
    <description>Anesthesia time; fluoroscopy time; contrast volume; estimated blood loss; % requiring transfusion; procedure time; ICU time; time to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Procedurally and to 5 Years</time_frame>
    <description>All-cause and aneurysm-related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>&gt;30 Days to 5 Years</time_frame>
    <description>All-cause mortality, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, blood loss &gt;1,000cc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Procedurally and to 5 Years</time_frame>
    <description>All serious and non-serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Dysfunction</measure>
    <time_frame>30 Days, 6 Months and Years 1 to 5</time_frame>
    <description>Reduction in estimated glomerular filtration rate (eGFR) &gt;30% from the preoperative value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm Rupture</measure>
    <time_frame>Procedurally and to 5 Years</time_frame>
    <description>Internal bleeding or leaking of blood from the aneurysm subsequent to the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to Open Repair</measure>
    <time_frame>Procedurally and to 5 Years</time_frame>
    <description>Open surgical repair of the aortic aneurysm due to unsuccessful delivery or deployment of the stent graft, due to complications or other clinical situations that precluded successful endovascular treatment, or at any time following initial successful endovascular treatment for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Blood Flow</measure>
    <time_frame>Pre-discharge, 30 Days, 6 Months, and Years 1 to 5</time_frame>
    <description>Ankle-brachial index measurements and changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Stent Graft Patency and Integrity</measure>
    <time_frame>30 Days, 6 Months, and Years 1 to 5</time_frame>
    <description>Patent luminal flow; absence of kinking, stenosis, occlusion, stent fracture, graft failure, or renal infarct &gt;30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Graft Patency and Integrity</measure>
    <time_frame>30 Days, 6 Months, and Years 1 to 5</time_frame>
    <description>Bifurcated and fenestrated stent graft patent luminal flow; absence of stent fracture or graft fatigue/failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endograft Performance</measure>
    <time_frame>30 Days, 6 Months, and Years 1 to 5</time_frame>
    <description>Change in aneurysm sac diameter from the first post-procedural measurement; incidence of endoleak; incidence of device migration; incidence of limb occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Procedures</measure>
    <time_frame>30 Days, 6 Months, and Years 1 to 5</time_frame>
    <description>Non-diagnostic intervention after the index procedure intended to correct or repair an endoleak (device-related: Type I (proximal or distal), Type III, Type IV; non-device related: Type II), device migration, or other device defect.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)</intervention_name>
    <description>Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System</description>
    <other_name>Ventana</other_name>
    <other_name>Xpand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adequate iliac/femoral access compatible with the required delivery systems

          -  Non-aneurysmal infrarenal aortic neck &lt;15mm in length

          -  Most caudal renal artery to aortoiliac bifurcation length &gt;= 70

          -  SMA to aortoiliac bifurcation length &gt;=90mm

          -  Proximal non-aneurysmal aortic neck below the SMA with diameter 18 to 34 mm, length
             &gt;=15mm and angle &lt;=60° to the aneurysm sac

          -  Angle &lt;=60° (clock face) between the SMA and CA

          -  Renal arteries both at or below the SMA by &lt;=35mm and within 30mm of each other
             axially, with 4 to 8mm lumen diameter, and with clockface angle of 90° to 210° to each
             other

          -  Common iliac artery distal fixation site with: distal fixation length &gt;=15mm, with
             diameter &gt;=10 mm and &lt;=23 mm and angle &lt;=90° to the aortic bifurcation

          -  Ability to preserve at least one hypogastric artery

        Exclusion Criteria:

          -  Life expectancy &lt;2 years as judged by the investigator

          -  Psychiatric or other condition that may interfere with the study

          -  Participating in the enrollment or 30-day follow-up phase of another clinical study

          -  Known allergy to any device component

          -  Coagulopathy or uncontrolled bleeding disorder

          -  Contraindication to contrast media or anticoagulants

          -  Ruptured, leaking, or mycotic aneurysm

          -  Aortic dissection Serum creatinine (S-Cr) level &gt;2.0 mg/dL

          -  Traumatic vascular injury

          -  Active systemic or localized groin infection

          -  Connective tissue disease (e.g., Marfan's Syndrome)

          -  Recent(within prior three months)cerebrovascular accident

          -  Recent(within prior three months)myocardial infarction

          -  Prior renal transplant

          -  Length of either renal artery to be stented &lt;12mm

          -  Significant occlusive disease or calcification of either renal artery (&gt;70%)

          -  An essential accessory renal artery

          -  Indispensable inferior mesenteric artery

          -  Untreated aneurysmal disease of the descending thoracic aorta

          -  Clinically significant mural thrombus circumferentially in the suprarenal segment

          -  Prior iliac artery stent implanted that may interfere with delivery system
             introduction

          -  Unsuitable vascular anatomy

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Clair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Holden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renato Mertens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universidad Catolica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universidad Catolica</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bureau de Recherche Clinique</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <zip>6800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1032</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Vascular Institute</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abdominal Aortic Aneurysm</keyword>
  <keyword>Fenestrated</keyword>
  <keyword>Renal Stent</keyword>
  <keyword>Juxtarenal</keyword>
  <keyword>Pararenal</keyword>
  <keyword>Endologix</keyword>
  <keyword>Renal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

